Clinical effect of Qiteng Tongbi fumigant combined with ganglioside in preventing neurotoxicity caused by mFOLFOX6 chemotherapy：A randomized controlled study

Abstract:

Objective：To investigate the clinical effect and safety of Qiteng Tongbi fumigant combined with ganglioside in preventing neurotoxicity caused by mFOLFOX6 chemotherapy in colorectal cancer patients，and to provide clinical evidence for integrated tradi－tional Chinese and Western medicine therapy in the treatment of peripheral neurotoxicity caused by chemotherapy. Methods：A total of 180 colorectal cancer patients who met the inclusion criteria and received mFOLFOX6 chemotherapy were randomly divided into treatment group 1（Qiteng Tongbi fumigant combined with ganglioside+chemotherapy），treatment group 2（ganglioside+chemotherapy），and control group（chemotherapy alone），with 60 patients in each group. Each course of treatment was 14 days，and all patients were treated for 12 courses. The three groups were evaluated and compared in terms of the incidence rate of peripheral neurotoxicity caused by oxaliplatin，electromyography（EMG） changes，and adverse reactions after treatment. Results：There was a significant differ－ence in the incidence rate of peripheral neurotoxicity between the treatment group 1，the treatment group 2，and the control group（χ2=21.899，P=0.000）. The time to peripheral neurotoxicity in the three groups was （129.920±4.615），（104.680±3.912），and （49.190±3.699） d，respectively，and there was a significant difference between the three groups（F=4 422.520，P=0.000）. There were significant differences between the three groups in sensory nerve conduction velocity（SNCV） and motor nerve conduction velocity（MNCV） of the common peroneal nerve[SNCV：（52.74±4.01） m/s vs. （45.55±4.21） m/s vs. （35.79±7.67） m/s，F=135.472，P=0.000；MNCV：（48.98±3.95） m/s vs. （44.69±4.18） m/s vs. （37.89±6.65） m/s，F=70.334，P=0.000]. There were no significant differences in the incidence rates of major adverse reactions between the three groups（P>0.05）. Conclusion：Qiteng Tongbi fumigant combined with ganglioside can significantly reduce the incidence rate of peripheral neurotoxicity caused by mFOLFOX6 chemotherapy and does not increase treatment-related adverse reactions. It is expected to become a superior and non-toxic treatment method for neurotoxicity caused by the chemotherapy drug oxaliplatin and holds promise for clinical application.